8-K: Silexion Therapeutics Faces Nasdaq Delisting, Plans Appeal and Market Transfer

Silexion Therapeutics Corp. received a delisting notice from Nasdaq due to non-compliance with minimum market value requirements and intends to appeal the decision while seeking a transfer to the Nasdaq Capital Market.

Summary

• Silexion Therapeutics Corp. (SLXN) received a delisting notice from the Nasdaq Listing Qualifications Department on May 22, 2025.
• The delisting notice stems from the company's failure to regain compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C).
• These rules require a minimum Market Value of Listed Securities (MVLS) of $50,000,000 and a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 for continued listing on the Nasdaq Global Market.
• The company's MVLS and MVPHS fell below these thresholds for 30 consecutive business days prior to November 19, 2024, triggering the initial deficiency notices.
• Silexion was granted a 180-day compliance period, ending May 19, 2025, but was unable to rectify the deficiencies.
• To regain compliance, the company needed to maintain an MVLS of $50,000,000 and an MVPHS of $15,000,000 for at least 10 consecutive business days.
• The company intends to appeal the delisting determination to the Nasdaq Hearings Panel by May 29, 2025.
• As part of its appeal strategy, Silexion plans to apply to transfer its listing to the Nasdaq Capital Market, which requires, among other things, at least $2.5 million of shareholders' equity.
• If the appeal is unsuccessful, trading in the company's ordinary shares and warrants (SLXNW) would be suspended at the opening of business on June 2, 2025, followed by a Form 25-NSE filing to remove them from Nasdaq listing and registration.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the formal delisting notice and the company's failure to meet listing standards. While the company plans an appeal and market transfer, these are reactive measures to a severe negative event and carry significant uncertainty.

Positives

• Silexion Therapeutics Corp. intends to appeal the delisting determination, which could temporarily stay the suspension of trading.
• The company plans to apply for a transfer to the Nasdaq Capital Market, which, if successful, would allow its securities to remain listed on a Nasdaq exchange.

Negatives

• Silexion Therapeutics Corp. received a formal delisting notice from Nasdaq due to non-compliance with listing standards.
• The company failed to meet the minimum Market Value of Listed Securities (MVLS) of $50,000,000 and Market Value of Publicly Held Shares (MVPHS) of $15,000,000 within the 180-day compliance period.
• If the appeal is unsuccessful, trading in the company's shares and warrants will be suspended on June 2, 2025, leading to full delisting.

Risks

• There is no assurance that the company's appeal of the delisting determination will be successful.
• There is no assurance that the company's request for transfer to the Nasdaq Capital Market will be successful.
• The company may not successfully comply with the Equity Standard (requiring at least $2.5 million of shareholders' equity) for listing on the Nasdaq Capital Market within any additional time period allotted by the Nasdaq Hearings Panel.
• Failure of the appeal or transfer could lead to the suspension of trading and removal of the company's securities from Nasdaq listing and registration.

Future Outlook

Silexion Therapeutics Corp. intends to appeal Nasdaq's delisting determination and apply to transfer its listing to the Nasdaq Capital Market, contingent on meeting the Equity Standard, including maintaining at least $2.5 million in shareholders' equity. However, there is no guarantee that the appeal or transfer will be successful, or that the company will meet the required standards within any additional time granted.

Management Comments

• The Company intends to request an appeal of the determination before the Nasdaq Hearings Panel in a timely manner.
• As part of our strategy for our appeal, we intend to apply to transfer the listing of our securities to the Nasdaq Capital Market, subject to our meeting the Equity Standard for continued listing on that market, which requires us to have, among other things, at least $2.5 million of shareholders equity.

Industry Context

This announcement highlights the ongoing challenges smaller or underperforming companies face in maintaining compliance with major exchange listing standards, particularly market capitalization requirements. Such delisting notices are not uncommon for companies that experience significant stock price declines or prolonged periods of low valuation, reflecting broader market sentiment or specific company performance issues within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C) set specific market value thresholds ($50M MVLS, $15M MVPHS) for continued listing on the Nasdaq Global Market, which Silexion Therapeutics failed to meet.
• The Nasdaq Capital Market's Equity Standard requires at least $2.5 million in shareholders' equity, a lower threshold compared to the Global Market's market value standards, which the company hopes to meet for continued listing.
• Compared to other biotech companies, maintaining sufficient market capitalization is a common challenge, especially for those in early development stages or facing clinical setbacks, as investor confidence directly impacts market value.

Stakeholder Impact

• Shareholders face significant risk of their shares being delisted from Nasdaq, potentially leading to reduced liquidity and price volatility.
• Investors may experience a loss of confidence in the company due to its inability to maintain listing compliance.
• Employees may face uncertainty regarding the company's future and its ability to raise capital or maintain operations if delisted.

Next Steps

• Silexion Therapeutics Corp. must request an appeal of the delisting determination before the Nasdaq Hearings Panel by May 29, 2025.
• The company intends to apply to transfer the listing of its securities to the Nasdaq Capital Market.
• The company must work to meet the Equity Standard for continued listing on the Nasdaq Capital Market, including having at least $2.5 million of shareholders' equity.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, Nasdaq delisting, Nasdaq Global Market, Nasdaq Capital Market, MVLS, MVPHS, listing compliance, shareholders equity, Form 8-K, SLXN, SLXNW